-
EBMT 2025 | Prof. Jun Ma: Spotlight on Cell and Gene Therapy as China’s Innovations Shine on the Global Stage
Hematology Frontier: Prof. Ma, welcome back to the EBMT Annual Meeting. What are your impressions this year? Are there any highlights that Chinese experts should pay particular attention to? Prof.…
-
EBMT 2025 | Prof. Jia Wei: Exploring Synergistic Mechanisms and Sequential Strategies in CAR-T Cell Therapy
Hematology Frontier: At this year’s EBMT Congress, your team presented three studies related to CAR-T therapy (A093, A134, A082). Among them, Study A093 showed that combining ASCT significantly improves long-term…
-
APASL Keynote Address | Academician Jiahong Dong: The Era of Precision Liver Surgery Powered by Smart Technology Has Arrived
Editor’s Note: On the morning of March 28, the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025) officially opened. During the keynote session, APASL 2025 Scientific Committee Chair, Academician Jiahong Dong of Beijing Tsinghua Changgung Hospital, delivered a keynote speech titled “Precision Surgical Treatment of Liver Diseases”…
-
EBMT 2025 | Prof. Fang Liu: From Predictive Models to Rare Disease Cures—Advancing Pediatric Cord Blood Transplantation
At the 2025 EBMT Annual Meeting, cord blood transplantation (UCBT) emerged as a transformative strategy in the treatment of pediatric hematologic malignancies. Hematopoietic stem cell transplantation (HSCT) remains a life-saving therapy, and UCBT is gaining attention for its unique clinical advantages. During the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation…
-
EBMT 2025 | Prof. Xiaoxia Hu: Focusing on Comprehensive Leukemia Management and Key Findings from the Ruijin Transplant Team
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a cornerstone in the treatment of various hematologic diseases. However, several peri-transplant challenges persist, particularly regarding the optimal timing of transplantation, the role of consolidation therapy, and maintenance strategies. At the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025), the transplant team…
-
EBMT 2025 | Prof. Qifa Liu: Emerging Strategies for GVHD Prevention—Mesenchymal Stem Cells and Fecal Microbiota Transplantation
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was held from March 30 to April 2 in the historic city of Florence, Italy. As one of the most influential global events in the field of hematology, the Annual Meeting gathered over 5,000 experts and scholars from around the…
-
EBMT 2025 | Prof. Erlie Jiang & Dr. Mingyang Wang: Using CBFB-MYH11 Fusion Transcript Ratios to Guide Transplant Timing in Low-Risk AML
Hematopoietic stem cell transplantation (HSCT) remains a curative treatment for numerous hematologic disorders. Despite its life-saving potential, many clinical challenges persist, particularly concerning patient selection, transplant timing, and long-term management. To enhance academic exchange and practical insights in the field of transplantation, Hematology Frontier launched the special feature “Transplantation Pathways Spotlight” during the 51st Annual…
-
EBMT 2025| Prof. He Huang: A Transplant-CAR-T-Nursing Triad Unleashes New Momentum in Hematology
Hematopoietic stem cell transplantation (HSCT) remains a cornerstone therapy for hematologic diseases. However, despite its curative potential, many clinical challenges persist. To promote academic exchange and practical innovation in the field of transplantation, Hematology Frontier launched the “Transplantation Pathways Spotlight” during the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT…
Connecting Medical Expertise through Media